Nootropics Comprehensive Study by Application (ADHD, Alzheimer, Narcolepsy, Memory Enhancement, Mood and Depression, Anxiety, Others), Drug (Prescription (Modafinil, Adderall, Methylphenidate, Memantine and Others), OTC (Omega-3s, Caffeine, L-Theanine, Racetams, Gingko Biloba, Creatine and Others)), Distribution Channel (Online (E-Commerce Stores), Offline (Pharmacy, Super Markets, Hyper Markets, and Department Stores)), Form (Powder, Liquid, Tablet, Capsules) Players and Region - Global Market Outlook to 2026

Report Objectives / Segmentation Covered

• ADHD
• Alzheimer
• Narcolepsy
• Memory Enhancement
• Mood and Depression
• Anxiety
• Others

• Prescription (Modafinil, Adderall, Methylphenidate, Memantine and Others)
• OTC (Omega-3s, Caffeine, L-Theanine, Racetams, Gingko Biloba, Creatine and Others)

• Online (E-Commerce Stores)
• Offline (Pharmacy, Super Markets, Hyper Markets, and Department Stores)

• Powder
• Liquid
• Tablet
• Capsules

• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • Italy
  • United Kingdom
  • Netherlands
  • Rest of Europe
• MEA
  • Middle East
  • Africa
• North America
  • United States
  • Canada
  • Mexico

• 1. Market Overview
  • 1.1. Introduction
  • 1.2. Scope/Objective of the Study
    • 1.2.1. Research Objective
• 2. Executive Summary
  • 2.1. Introduction
• 3. Market Dynamics
  • 3.1. Introduction
  • 3.2. Market Drivers
    • 3.2.1. Increase in Patients Suffering from Attention Deficit Hyperactivity Disorder (ADHD)
    • 3.2.2. Surge in Alzheimer Patients
    • 3.2.3. Students Using Smart Drug to Enhance Academic Performance
  • 3.3. Market Challenges
    • 3.3.1. Presence of Lot of OTC Players in the Market
  • 3.4. Market Trends
    • 3.4.1. Students Study Drug or Smart Drug is one of the Fastest Growing Segment
• 4. Market Factor Analysis
  • 4.1. Porters Five Forces
  • 4.2. Supply/Value Chain
  • 4.3. PESTEL analysis
  • 4.4. Market Entropy
  • 4.5. Patent/Trademark Analysis
• 5. Global Nootropics, by Application, Drug, Distribution Channel, Form and Region (value, volume and price ) (2015-2020)
  • 5.1. Introduction
  • 5.2. Global Nootropics (Value)
    • 5.2.1. Global Nootropics by: Application (Value)
      • 5.2.1.1. ADHD
      • 5.2.1.2. Alzheimer
      • 5.2.1.3. Narcolepsy
      • 5.2.1.4. Memory Enhancement
      • 5.2.1.5. Mood and Depression
      • 5.2.1.6. Anxiety
      • 5.2.1.7. Others
    • 5.2.2. Global Nootropics by: Drug (Value)
      • 5.2.2.1. Prescription (Modafinil, Adderall, Methylphenidate, Memantine and Others)
      • 5.2.2.2. OTC (Omega-3s, Caffeine, L-Theanine, Racetams, Gingko Biloba, Creatine and Others)
    • 5.2.3. Global Nootropics by: Distribution Channel (Value)
      • 5.2.3.1. Online (E-Commerce Stores)
      • 5.2.3.2. Offline (Pharmacy, Super Markets, Hyper Markets, and Department Stores)
    • 5.2.4. Global Nootropics by: Form (Value)
      • 5.2.4.1. Powder
      • 5.2.4.2. Liquid
      • 5.2.4.3. Tablet
      • 5.2.4.4. Capsules
    • 5.2.5. Global Nootropics Region
      • 5.2.5.1. South America
        • 5.2.5.1.1. Brazil
        • 5.2.5.1.2. Argentina
        • 5.2.5.1.3. Rest of South America
      • 5.2.5.2. Asia Pacific
        • 5.2.5.2.1. China
        • 5.2.5.2.2. Japan
        • 5.2.5.2.3. India
        • 5.2.5.2.4. South Korea
        • 5.2.5.2.5. Taiwan
        • 5.2.5.2.6. Australia
        • 5.2.5.2.7. Rest of Asia-Pacific
      • 5.2.5.3. Europe
        • 5.2.5.3.1. Germany
        • 5.2.5.3.2. France
        • 5.2.5.3.3. Italy
        • 5.2.5.3.4. United Kingdom
        • 5.2.5.3.5. Netherlands
        • 5.2.5.3.6. Rest of Europe
      • 5.2.5.4. MEA
        • 5.2.5.4.1. Middle East
        • 5.2.5.4.2. Africa
      • 5.2.5.5. North America
        • 5.2.5.5.1. United States
        • 5.2.5.5.2. Canada
        • 5.2.5.5.3. Mexico
  • 5.3. Global Nootropics (Volume)
    • 5.3.1. Global Nootropics by: Application (Volume)
      • 5.3.1.1. ADHD
      • 5.3.1.2. Alzheimer
      • 5.3.1.3. Narcolepsy
      • 5.3.1.4. Memory Enhancement
      • 5.3.1.5. Mood and Depression
      • 5.3.1.6. Anxiety
      • 5.3.1.7. Others
    • 5.3.2. Global Nootropics by: Drug (Volume)
      • 5.3.2.1. Prescription (Modafinil, Adderall, Methylphenidate, Memantine and Others)
      • 5.3.2.2. OTC (Omega-3s, Caffeine, L-Theanine, Racetams, Gingko Biloba, Creatine and Others)
    • 5.3.3. Global Nootropics by: Distribution Channel (Volume)
      • 5.3.3.1. Online (E-Commerce Stores)
      • 5.3.3.2. Offline (Pharmacy, Super Markets, Hyper Markets, and Department Stores)
    • 5.3.4. Global Nootropics by: Form (Volume)
      • 5.3.4.1. Powder
      • 5.3.4.2. Liquid
      • 5.3.4.3. Tablet
      • 5.3.4.4. Capsules
    • 5.3.5. Global Nootropics Region
      • 5.3.5.1. South America
        • 5.3.5.1.1. Brazil
        • 5.3.5.1.2. Argentina
        • 5.3.5.1.3. Rest of South America
      • 5.3.5.2. Asia Pacific
        • 5.3.5.2.1. China
        • 5.3.5.2.2. Japan
        • 5.3.5.2.3. India
        • 5.3.5.2.4. South Korea
        • 5.3.5.2.5. Taiwan
        • 5.3.5.2.6. Australia
        • 5.3.5.2.7. Rest of Asia-Pacific
      • 5.3.5.3. Europe
        • 5.3.5.3.1. Germany
        • 5.3.5.3.2. France
        • 5.3.5.3.3. Italy
        • 5.3.5.3.4. United Kingdom
        • 5.3.5.3.5. Netherlands
        • 5.3.5.3.6. Rest of Europe
      • 5.3.5.4. MEA
        • 5.3.5.4.1. Middle East
        • 5.3.5.4.2. Africa
      • 5.3.5.5. North America
        • 5.3.5.5.1. United States
        • 5.3.5.5.2. Canada
        • 5.3.5.5.3. Mexico
  • 5.4. Global Nootropics (Price)
• 6. Nootropics: Manufacturers/Players Analysis
  • 6.1. Competitive Landscape
    • 6.1.1. Market Share Analysis
      • 6.1.1.1. Top 3
      • 6.1.1.2. Top 5
  • 6.2. Peer Group Analysis (2020)
  • 6.3. BCG Matrix
  • 6.4. Company Profile
    • 6.4.1. Purelife Bioscience Co., Ltd. (China)
      • 6.4.1.1. Business Overview
      • 6.4.1.2. Products/Services Offerings
      • 6.4.1.3. Financial Analysis
      • 6.4.1.4. SWOT Analysis
    • 6.4.2. Cephalon, Inc. (United States)
      • 6.4.2.1. Business Overview
      • 6.4.2.2. Products/Services Offerings
      • 6.4.2.3. Financial Analysis
      • 6.4.2.4. SWOT Analysis
    • 6.4.3. HVMN Inc. (United States)
      • 6.4.3.1. Business Overview
      • 6.4.3.2. Products/Services Offerings
      • 6.4.3.3. Financial Analysis
      • 6.4.3.4. SWOT Analysis
    • 6.4.4. Accelerated Intelligence, Inc. (United Kingdom)
      • 6.4.4.1. Business Overview
      • 6.4.4.2. Products/Services Offerings
      • 6.4.4.3. Financial Analysis
      • 6.4.4.4. SWOT Analysis
    • 6.4.5. AlternaScript (United States)
      • 6.4.5.1. Business Overview
      • 6.4.5.2. Products/Services Offerings
      • 6.4.5.3. Financial Analysis
      • 6.4.5.4. SWOT Analysis
    • 6.4.6. TruBrain (United States)
      • 6.4.6.1. Business Overview
      • 6.4.6.2. Products/Services Offerings
      • 6.4.6.3. Financial Analysis
      • 6.4.6.4. SWOT Analysis
    • 6.4.7. Peak Nootropics (United States)
      • 6.4.7.1. Business Overview
      • 6.4.7.2. Products/Services Offerings
      • 6.4.7.3. Financial Analysis
      • 6.4.7.4. SWOT Analysis
    • 6.4.8. Nootrico (United States)
      • 6.4.8.1. Business Overview
      • 6.4.8.2. Products/Services Offerings
      • 6.4.8.3. Financial Analysis
      • 6.4.8.4. SWOT Analysis
    • 6.4.9. NooCube (Cyprus)
      • 6.4.9.1. Business Overview
      • 6.4.9.2. Products/Services Offerings
      • 6.4.9.3. Financial Analysis
      • 6.4.9.4. SWOT Analysis
    • 6.4.10. Opti-Nutra Ltd. (United Kingdom)
      • 6.4.10.1. Business Overview
      • 6.4.10.2. Products/Services Offerings
      • 6.4.10.3. Financial Analysis
      • 6.4.10.4. SWOT Analysis
• 7. Global Nootropics Sale, by Application, Drug, Distribution Channel, Form and Region (value, volume and price ) (2021-2026)
  • 7.1. Introduction
  • 7.2. Global Nootropics (Value)
    • 7.2.1. Global Nootropics by: Application (Value)
      • 7.2.1.1. ADHD
      • 7.2.1.2. Alzheimer
      • 7.2.1.3. Narcolepsy
      • 7.2.1.4. Memory Enhancement
      • 7.2.1.5. Mood and Depression
      • 7.2.1.6. Anxiety
      • 7.2.1.7. Others
    • 7.2.2. Global Nootropics by: Drug (Value)
      • 7.2.2.1. Prescription (Modafinil, Adderall, Methylphenidate, Memantine and Others)
      • 7.2.2.2. OTC (Omega-3s, Caffeine, L-Theanine, Racetams, Gingko Biloba, Creatine and Others)
    • 7.2.3. Global Nootropics by: Distribution Channel (Value)
      • 7.2.3.1. Online (E-Commerce Stores)
      • 7.2.3.2. Offline (Pharmacy, Super Markets, Hyper Markets, and Department Stores)
    • 7.2.4. Global Nootropics by: Form (Value)
      • 7.2.4.1. Powder
      • 7.2.4.2. Liquid
      • 7.2.4.3. Tablet
      • 7.2.4.4. Capsules
    • 7.2.5. Global Nootropics Region
      • 7.2.5.1. South America
        • 7.2.5.1.1. Brazil
        • 7.2.5.1.2. Argentina
        • 7.2.5.1.3. Rest of South America
      • 7.2.5.2. Asia Pacific
        • 7.2.5.2.1. China
        • 7.2.5.2.2. Japan
        • 7.2.5.2.3. India
        • 7.2.5.2.4. South Korea
        • 7.2.5.2.5. Taiwan
        • 7.2.5.2.6. Australia
        • 7.2.5.2.7. Rest of Asia-Pacific
      • 7.2.5.3. Europe
        • 7.2.5.3.1. Germany
        • 7.2.5.3.2. France
        • 7.2.5.3.3. Italy
        • 7.2.5.3.4. United Kingdom
        • 7.2.5.3.5. Netherlands
        • 7.2.5.3.6. Rest of Europe
      • 7.2.5.4. MEA
        • 7.2.5.4.1. Middle East
        • 7.2.5.4.2. Africa
      • 7.2.5.5. North America
        • 7.2.5.5.1. United States
        • 7.2.5.5.2. Canada
        • 7.2.5.5.3. Mexico
  • 7.3. Global Nootropics (Volume)
    • 7.3.1. Global Nootropics by: Application (Volume)
      • 7.3.1.1. ADHD
      • 7.3.1.2. Alzheimer
      • 7.3.1.3. Narcolepsy
      • 7.3.1.4. Memory Enhancement
      • 7.3.1.5. Mood and Depression
      • 7.3.1.6. Anxiety
      • 7.3.1.7. Others
    • 7.3.2. Global Nootropics by: Drug (Volume)
      • 7.3.2.1. Prescription (Modafinil, Adderall, Methylphenidate, Memantine and Others)
      • 7.3.2.2. OTC (Omega-3s, Caffeine, L-Theanine, Racetams, Gingko Biloba, Creatine and Others)
    • 7.3.3. Global Nootropics by: Distribution Channel (Volume)
      • 7.3.3.1. Online (E-Commerce Stores)
      • 7.3.3.2. Offline (Pharmacy, Super Markets, Hyper Markets, and Department Stores)
    • 7.3.4. Global Nootropics by: Form (Volume)
      • 7.3.4.1. Powder
      • 7.3.4.2. Liquid
      • 7.3.4.3. Tablet
      • 7.3.4.4. Capsules
    • 7.3.5. Global Nootropics Region
      • 7.3.5.1. South America
        • 7.3.5.1.1. Brazil
        • 7.3.5.1.2. Argentina
        • 7.3.5.1.3. Rest of South America
      • 7.3.5.2. Asia Pacific
        • 7.3.5.2.1. China
        • 7.3.5.2.2. Japan
        • 7.3.5.2.3. India
        • 7.3.5.2.4. South Korea
        • 7.3.5.2.5. Taiwan
        • 7.3.5.2.6. Australia
        • 7.3.5.2.7. Rest of Asia-Pacific
      • 7.3.5.3. Europe
        • 7.3.5.3.1. Germany
        • 7.3.5.3.2. France
        • 7.3.5.3.3. Italy
        • 7.3.5.3.4. United Kingdom
        • 7.3.5.3.5. Netherlands
        • 7.3.5.3.6. Rest of Europe
      • 7.3.5.4. MEA
        • 7.3.5.4.1. Middle East
        • 7.3.5.4.2. Africa
      • 7.3.5.5. North America
        • 7.3.5.5.1. United States
        • 7.3.5.5.2. Canada
        • 7.3.5.5.3. Mexico
  • 7.4. Global Nootropics (Price)
• 8. Appendix
  • 8.1. Acronyms
• 9. Methodology and Data Source
  • 9.1. Methodology/Research Approach
    • 9.1.1. Research Programs/Design
    • 9.1.2. Market Size Estimation
    • 9.1.3. Market Breakdown and Data Triangulation
  • 9.2. Data Source
    • 9.2.1. Secondary Sources
    • 9.2.2. Primary Sources
  • 9.3. Disclaimer

• Table 1. Nootropics: by Application(USD Million)
• Table 2. Nootropics ADHD , by Region USD Million (2015-2020)
• Table 3. Nootropics Alzheimer , by Region USD Million (2015-2020)
• Table 4. Nootropics Narcolepsy , by Region USD Million (2015-2020)
• Table 5. Nootropics Memory Enhancement , by Region USD Million (2015-2020)
• Table 6. Nootropics Mood and Depression , by Region USD Million (2015-2020)
• Table 7. Nootropics Anxiety , by Region USD Million (2015-2020)
• Table 8. Nootropics Others , by Region USD Million (2015-2020)
• Table 9. Nootropics: by Drug(USD Million)
• Table 10. Nootropics Prescription (Modafinil, Adderall, Methylphenidate, Memantine and Others) , by Region USD Million (2015-2020)
• Table 11. Nootropics OTC (Omega-3s, Caffeine, L-Theanine, Racetams, Gingko Biloba, Creatine and Others) , by Region USD Million (2015-2020)
• Table 12. Nootropics: by Distribution Channel(USD Million)
• Table 13. Nootropics Online (E-Commerce Stores) , by Region USD Million (2015-2020)
• Table 14. Nootropics Offline (Pharmacy, Super Markets, Hyper Markets, and Department Stores) , by Region USD Million (2015-2020)
• Table 15. Nootropics: by Form(USD Million)
• Table 16. Nootropics Powder , by Region USD Million (2015-2020)
• Table 17. Nootropics Liquid , by Region USD Million (2015-2020)
• Table 18. Nootropics Tablet , by Region USD Million (2015-2020)
• Table 19. Nootropics Capsules , by Region USD Million (2015-2020)
• Table 20. South America Nootropics, by Country USD Million (2015-2020)
• Table 21. South America Nootropics, by Application USD Million (2015-2020)
• Table 22. South America Nootropics, by Drug USD Million (2015-2020)
• Table 23. South America Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 24. South America Nootropics, by Form USD Million (2015-2020)
• Table 25. Brazil Nootropics, by Application USD Million (2015-2020)
• Table 26. Brazil Nootropics, by Drug USD Million (2015-2020)
• Table 27. Brazil Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 28. Brazil Nootropics, by Form USD Million (2015-2020)
• Table 29. Argentina Nootropics, by Application USD Million (2015-2020)
• Table 30. Argentina Nootropics, by Drug USD Million (2015-2020)
• Table 31. Argentina Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 32. Argentina Nootropics, by Form USD Million (2015-2020)
• Table 33. Rest of South America Nootropics, by Application USD Million (2015-2020)
• Table 34. Rest of South America Nootropics, by Drug USD Million (2015-2020)
• Table 35. Rest of South America Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 36. Rest of South America Nootropics, by Form USD Million (2015-2020)
• Table 37. Asia Pacific Nootropics, by Country USD Million (2015-2020)
• Table 38. Asia Pacific Nootropics, by Application USD Million (2015-2020)
• Table 39. Asia Pacific Nootropics, by Drug USD Million (2015-2020)
• Table 40. Asia Pacific Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 41. Asia Pacific Nootropics, by Form USD Million (2015-2020)
• Table 42. China Nootropics, by Application USD Million (2015-2020)
• Table 43. China Nootropics, by Drug USD Million (2015-2020)
• Table 44. China Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 45. China Nootropics, by Form USD Million (2015-2020)
• Table 46. Japan Nootropics, by Application USD Million (2015-2020)
• Table 47. Japan Nootropics, by Drug USD Million (2015-2020)
• Table 48. Japan Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 49. Japan Nootropics, by Form USD Million (2015-2020)
• Table 50. India Nootropics, by Application USD Million (2015-2020)
• Table 51. India Nootropics, by Drug USD Million (2015-2020)
• Table 52. India Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 53. India Nootropics, by Form USD Million (2015-2020)
• Table 54. South Korea Nootropics, by Application USD Million (2015-2020)
• Table 55. South Korea Nootropics, by Drug USD Million (2015-2020)
• Table 56. South Korea Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 57. South Korea Nootropics, by Form USD Million (2015-2020)
• Table 58. Taiwan Nootropics, by Application USD Million (2015-2020)
• Table 59. Taiwan Nootropics, by Drug USD Million (2015-2020)
• Table 60. Taiwan Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 61. Taiwan Nootropics, by Form USD Million (2015-2020)
• Table 62. Australia Nootropics, by Application USD Million (2015-2020)
• Table 63. Australia Nootropics, by Drug USD Million (2015-2020)
• Table 64. Australia Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 65. Australia Nootropics, by Form USD Million (2015-2020)
• Table 66. Rest of Asia-Pacific Nootropics, by Application USD Million (2015-2020)
• Table 67. Rest of Asia-Pacific Nootropics, by Drug USD Million (2015-2020)
• Table 68. Rest of Asia-Pacific Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 69. Rest of Asia-Pacific Nootropics, by Form USD Million (2015-2020)
• Table 70. Europe Nootropics, by Country USD Million (2015-2020)
• Table 71. Europe Nootropics, by Application USD Million (2015-2020)
• Table 72. Europe Nootropics, by Drug USD Million (2015-2020)
• Table 73. Europe Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 74. Europe Nootropics, by Form USD Million (2015-2020)
• Table 75. Germany Nootropics, by Application USD Million (2015-2020)
• Table 76. Germany Nootropics, by Drug USD Million (2015-2020)
• Table 77. Germany Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 78. Germany Nootropics, by Form USD Million (2015-2020)
• Table 79. France Nootropics, by Application USD Million (2015-2020)
• Table 80. France Nootropics, by Drug USD Million (2015-2020)
• Table 81. France Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 82. France Nootropics, by Form USD Million (2015-2020)
• Table 83. Italy Nootropics, by Application USD Million (2015-2020)
• Table 84. Italy Nootropics, by Drug USD Million (2015-2020)
• Table 85. Italy Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 86. Italy Nootropics, by Form USD Million (2015-2020)
• Table 87. United Kingdom Nootropics, by Application USD Million (2015-2020)
• Table 88. United Kingdom Nootropics, by Drug USD Million (2015-2020)
• Table 89. United Kingdom Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 90. United Kingdom Nootropics, by Form USD Million (2015-2020)
• Table 91. Netherlands Nootropics, by Application USD Million (2015-2020)
• Table 92. Netherlands Nootropics, by Drug USD Million (2015-2020)
• Table 93. Netherlands Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 94. Netherlands Nootropics, by Form USD Million (2015-2020)
• Table 95. Rest of Europe Nootropics, by Application USD Million (2015-2020)
• Table 96. Rest of Europe Nootropics, by Drug USD Million (2015-2020)
• Table 97. Rest of Europe Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 98. Rest of Europe Nootropics, by Form USD Million (2015-2020)
• Table 99. MEA Nootropics, by Country USD Million (2015-2020)
• Table 100. MEA Nootropics, by Application USD Million (2015-2020)
• Table 101. MEA Nootropics, by Drug USD Million (2015-2020)
• Table 102. MEA Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 103. MEA Nootropics, by Form USD Million (2015-2020)
• Table 104. Middle East Nootropics, by Application USD Million (2015-2020)
• Table 105. Middle East Nootropics, by Drug USD Million (2015-2020)
• Table 106. Middle East Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 107. Middle East Nootropics, by Form USD Million (2015-2020)
• Table 108. Africa Nootropics, by Application USD Million (2015-2020)
• Table 109. Africa Nootropics, by Drug USD Million (2015-2020)
• Table 110. Africa Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 111. Africa Nootropics, by Form USD Million (2015-2020)
• Table 112. North America Nootropics, by Country USD Million (2015-2020)
• Table 113. North America Nootropics, by Application USD Million (2015-2020)
• Table 114. North America Nootropics, by Drug USD Million (2015-2020)
• Table 115. North America Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 116. North America Nootropics, by Form USD Million (2015-2020)
• Table 117. United States Nootropics, by Application USD Million (2015-2020)
• Table 118. United States Nootropics, by Drug USD Million (2015-2020)
• Table 119. United States Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 120. United States Nootropics, by Form USD Million (2015-2020)
• Table 121. Canada Nootropics, by Application USD Million (2015-2020)
• Table 122. Canada Nootropics, by Drug USD Million (2015-2020)
• Table 123. Canada Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 124. Canada Nootropics, by Form USD Million (2015-2020)
• Table 125. Mexico Nootropics, by Application USD Million (2015-2020)
• Table 126. Mexico Nootropics, by Drug USD Million (2015-2020)
• Table 127. Mexico Nootropics, by Distribution Channel USD Million (2015-2020)
• Table 128. Mexico Nootropics, by Form USD Million (2015-2020)
• Table 129. Nootropics Sales: by Application(K Tons)
• Table 130. Nootropics Sales ADHD , by Region K Tons (2015-2020)
• Table 131. Nootropics Sales Alzheimer , by Region K Tons (2015-2020)
• Table 132. Nootropics Sales Narcolepsy , by Region K Tons (2015-2020)
• Table 133. Nootropics Sales Memory Enhancement , by Region K Tons (2015-2020)
• Table 134. Nootropics Sales Mood and Depression , by Region K Tons (2015-2020)
• Table 135. Nootropics Sales Anxiety , by Region K Tons (2015-2020)
• Table 136. Nootropics Sales Others , by Region K Tons (2015-2020)
• Table 137. Nootropics Sales: by Drug(K Tons)
• Table 138. Nootropics Sales Prescription (Modafinil, Adderall, Methylphenidate, Memantine and Others) , by Region K Tons (2015-2020)
• Table 139. Nootropics Sales OTC (Omega-3s, Caffeine, L-Theanine, Racetams, Gingko Biloba, Creatine and Others) , by Region K Tons (2015-2020)
• Table 140. Nootropics Sales: by Distribution Channel(K Tons)
• Table 141. Nootropics Sales Online (E-Commerce Stores) , by Region K Tons (2015-2020)
• Table 142. Nootropics Sales Offline (Pharmacy, Super Markets, Hyper Markets, and Department Stores) , by Region K Tons (2015-2020)
• Table 143. Nootropics Sales: by Form(K Tons)
• Table 144. Nootropics Sales Powder , by Region K Tons (2015-2020)
• Table 145. Nootropics Sales Liquid , by Region K Tons (2015-2020)
• Table 146. Nootropics Sales Tablet , by Region K Tons (2015-2020)
• Table 147. Nootropics Sales Capsules , by Region K Tons (2015-2020)
• Table 148. South America Nootropics Sales, by Country K Tons (2015-2020)
• Table 149. South America Nootropics Sales, by Application K Tons (2015-2020)
• Table 150. South America Nootropics Sales, by Drug K Tons (2015-2020)
• Table 151. South America Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 152. South America Nootropics Sales, by Form K Tons (2015-2020)
• Table 153. Brazil Nootropics Sales, by Application K Tons (2015-2020)
• Table 154. Brazil Nootropics Sales, by Drug K Tons (2015-2020)
• Table 155. Brazil Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 156. Brazil Nootropics Sales, by Form K Tons (2015-2020)
• Table 157. Argentina Nootropics Sales, by Application K Tons (2015-2020)
• Table 158. Argentina Nootropics Sales, by Drug K Tons (2015-2020)
• Table 159. Argentina Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 160. Argentina Nootropics Sales, by Form K Tons (2015-2020)
• Table 161. Rest of South America Nootropics Sales, by Application K Tons (2015-2020)
• Table 162. Rest of South America Nootropics Sales, by Drug K Tons (2015-2020)
• Table 163. Rest of South America Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 164. Rest of South America Nootropics Sales, by Form K Tons (2015-2020)
• Table 165. Asia Pacific Nootropics Sales, by Country K Tons (2015-2020)
• Table 166. Asia Pacific Nootropics Sales, by Application K Tons (2015-2020)
• Table 167. Asia Pacific Nootropics Sales, by Drug K Tons (2015-2020)
• Table 168. Asia Pacific Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 169. Asia Pacific Nootropics Sales, by Form K Tons (2015-2020)
• Table 170. China Nootropics Sales, by Application K Tons (2015-2020)
• Table 171. China Nootropics Sales, by Drug K Tons (2015-2020)
• Table 172. China Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 173. China Nootropics Sales, by Form K Tons (2015-2020)
• Table 174. Japan Nootropics Sales, by Application K Tons (2015-2020)
• Table 175. Japan Nootropics Sales, by Drug K Tons (2015-2020)
• Table 176. Japan Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 177. Japan Nootropics Sales, by Form K Tons (2015-2020)
• Table 178. India Nootropics Sales, by Application K Tons (2015-2020)
• Table 179. India Nootropics Sales, by Drug K Tons (2015-2020)
• Table 180. India Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 181. India Nootropics Sales, by Form K Tons (2015-2020)
• Table 182. South Korea Nootropics Sales, by Application K Tons (2015-2020)
• Table 183. South Korea Nootropics Sales, by Drug K Tons (2015-2020)
• Table 184. South Korea Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 185. South Korea Nootropics Sales, by Form K Tons (2015-2020)
• Table 186. Taiwan Nootropics Sales, by Application K Tons (2015-2020)
• Table 187. Taiwan Nootropics Sales, by Drug K Tons (2015-2020)
• Table 188. Taiwan Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 189. Taiwan Nootropics Sales, by Form K Tons (2015-2020)
• Table 190. Australia Nootropics Sales, by Application K Tons (2015-2020)
• Table 191. Australia Nootropics Sales, by Drug K Tons (2015-2020)
• Table 192. Australia Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 193. Australia Nootropics Sales, by Form K Tons (2015-2020)
• Table 194. Rest of Asia-Pacific Nootropics Sales, by Application K Tons (2015-2020)
• Table 195. Rest of Asia-Pacific Nootropics Sales, by Drug K Tons (2015-2020)
• Table 196. Rest of Asia-Pacific Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 197. Rest of Asia-Pacific Nootropics Sales, by Form K Tons (2015-2020)
• Table 198. Europe Nootropics Sales, by Country K Tons (2015-2020)
• Table 199. Europe Nootropics Sales, by Application K Tons (2015-2020)
• Table 200. Europe Nootropics Sales, by Drug K Tons (2015-2020)
• Table 201. Europe Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 202. Europe Nootropics Sales, by Form K Tons (2015-2020)
• Table 203. Germany Nootropics Sales, by Application K Tons (2015-2020)
• Table 204. Germany Nootropics Sales, by Drug K Tons (2015-2020)
• Table 205. Germany Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 206. Germany Nootropics Sales, by Form K Tons (2015-2020)
• Table 207. France Nootropics Sales, by Application K Tons (2015-2020)
• Table 208. France Nootropics Sales, by Drug K Tons (2015-2020)
• Table 209. France Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 210. France Nootropics Sales, by Form K Tons (2015-2020)
• Table 211. Italy Nootropics Sales, by Application K Tons (2015-2020)
• Table 212. Italy Nootropics Sales, by Drug K Tons (2015-2020)
• Table 213. Italy Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 214. Italy Nootropics Sales, by Form K Tons (2015-2020)
• Table 215. United Kingdom Nootropics Sales, by Application K Tons (2015-2020)
• Table 216. United Kingdom Nootropics Sales, by Drug K Tons (2015-2020)
• Table 217. United Kingdom Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 218. United Kingdom Nootropics Sales, by Form K Tons (2015-2020)
• Table 219. Netherlands Nootropics Sales, by Application K Tons (2015-2020)
• Table 220. Netherlands Nootropics Sales, by Drug K Tons (2015-2020)
• Table 221. Netherlands Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 222. Netherlands Nootropics Sales, by Form K Tons (2015-2020)
• Table 223. Rest of Europe Nootropics Sales, by Application K Tons (2015-2020)
• Table 224. Rest of Europe Nootropics Sales, by Drug K Tons (2015-2020)
• Table 225. Rest of Europe Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 226. Rest of Europe Nootropics Sales, by Form K Tons (2015-2020)
• Table 227. MEA Nootropics Sales, by Country K Tons (2015-2020)
• Table 228. MEA Nootropics Sales, by Application K Tons (2015-2020)
• Table 229. MEA Nootropics Sales, by Drug K Tons (2015-2020)
• Table 230. MEA Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 231. MEA Nootropics Sales, by Form K Tons (2015-2020)
• Table 232. Middle East Nootropics Sales, by Application K Tons (2015-2020)
• Table 233. Middle East Nootropics Sales, by Drug K Tons (2015-2020)
• Table 234. Middle East Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 235. Middle East Nootropics Sales, by Form K Tons (2015-2020)
• Table 236. Africa Nootropics Sales, by Application K Tons (2015-2020)
• Table 237. Africa Nootropics Sales, by Drug K Tons (2015-2020)
• Table 238. Africa Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 239. Africa Nootropics Sales, by Form K Tons (2015-2020)
• Table 240. North America Nootropics Sales, by Country K Tons (2015-2020)
• Table 241. North America Nootropics Sales, by Application K Tons (2015-2020)
• Table 242. North America Nootropics Sales, by Drug K Tons (2015-2020)
• Table 243. North America Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 244. North America Nootropics Sales, by Form K Tons (2015-2020)
• Table 245. United States Nootropics Sales, by Application K Tons (2015-2020)
• Table 246. United States Nootropics Sales, by Drug K Tons (2015-2020)
• Table 247. United States Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 248. United States Nootropics Sales, by Form K Tons (2015-2020)
• Table 249. Canada Nootropics Sales, by Application K Tons (2015-2020)
• Table 250. Canada Nootropics Sales, by Drug K Tons (2015-2020)
• Table 251. Canada Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 252. Canada Nootropics Sales, by Form K Tons (2015-2020)
• Table 253. Mexico Nootropics Sales, by Application K Tons (2015-2020)
• Table 254. Mexico Nootropics Sales, by Drug K Tons (2015-2020)
• Table 255. Mexico Nootropics Sales, by Distribution Channel K Tons (2015-2020)
• Table 256. Mexico Nootropics Sales, by Form K Tons (2015-2020)
• Table 257. Company Basic Information, Sales Area and Its Competitors
• Table 258. Company Basic Information, Sales Area and Its Competitors
• Table 259. Company Basic Information, Sales Area and Its Competitors
• Table 260. Company Basic Information, Sales Area and Its Competitors
• Table 261. Company Basic Information, Sales Area and Its Competitors
• Table 262. Company Basic Information, Sales Area and Its Competitors
• Table 263. Company Basic Information, Sales Area and Its Competitors
• Table 264. Company Basic Information, Sales Area and Its Competitors
• Table 265. Company Basic Information, Sales Area and Its Competitors
• Table 266. Company Basic Information, Sales Area and Its Competitors
• Table 267. Nootropics: by Application(USD Million)
• Table 268. Nootropics ADHD , by Region USD Million (2021-2026)
• Table 269. Nootropics Alzheimer , by Region USD Million (2021-2026)
• Table 270. Nootropics Narcolepsy , by Region USD Million (2021-2026)
• Table 271. Nootropics Memory Enhancement , by Region USD Million (2021-2026)
• Table 272. Nootropics Mood and Depression , by Region USD Million (2021-2026)
• Table 273. Nootropics Anxiety , by Region USD Million (2021-2026)
• Table 274. Nootropics Others , by Region USD Million (2021-2026)
• Table 275. Nootropics: by Drug(USD Million)
• Table 276. Nootropics Prescription (Modafinil, Adderall, Methylphenidate, Memantine and Others) , by Region USD Million (2021-2026)
• Table 277. Nootropics OTC (Omega-3s, Caffeine, L-Theanine, Racetams, Gingko Biloba, Creatine and Others) , by Region USD Million (2021-2026)
• Table 278. Nootropics: by Distribution Channel(USD Million)
• Table 279. Nootropics Online (E-Commerce Stores) , by Region USD Million (2021-2026)
• Table 280. Nootropics Offline (Pharmacy, Super Markets, Hyper Markets, and Department Stores) , by Region USD Million (2021-2026)
• Table 281. Nootropics: by Form(USD Million)
• Table 282. Nootropics Powder , by Region USD Million (2021-2026)
• Table 283. Nootropics Liquid , by Region USD Million (2021-2026)
• Table 284. Nootropics Tablet , by Region USD Million (2021-2026)
• Table 285. Nootropics Capsules , by Region USD Million (2021-2026)
• Table 286. South America Nootropics, by Country USD Million (2021-2026)
• Table 287. South America Nootropics, by Application USD Million (2021-2026)
• Table 288. South America Nootropics, by Drug USD Million (2021-2026)
• Table 289. South America Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 290. South America Nootropics, by Form USD Million (2021-2026)
• Table 291. Brazil Nootropics, by Application USD Million (2021-2026)
• Table 292. Brazil Nootropics, by Drug USD Million (2021-2026)
• Table 293. Brazil Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 294. Brazil Nootropics, by Form USD Million (2021-2026)
• Table 295. Argentina Nootropics, by Application USD Million (2021-2026)
• Table 296. Argentina Nootropics, by Drug USD Million (2021-2026)
• Table 297. Argentina Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 298. Argentina Nootropics, by Form USD Million (2021-2026)
• Table 299. Rest of South America Nootropics, by Application USD Million (2021-2026)
• Table 300. Rest of South America Nootropics, by Drug USD Million (2021-2026)
• Table 301. Rest of South America Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 302. Rest of South America Nootropics, by Form USD Million (2021-2026)
• Table 303. Asia Pacific Nootropics, by Country USD Million (2021-2026)
• Table 304. Asia Pacific Nootropics, by Application USD Million (2021-2026)
• Table 305. Asia Pacific Nootropics, by Drug USD Million (2021-2026)
• Table 306. Asia Pacific Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 307. Asia Pacific Nootropics, by Form USD Million (2021-2026)
• Table 308. China Nootropics, by Application USD Million (2021-2026)
• Table 309. China Nootropics, by Drug USD Million (2021-2026)
• Table 310. China Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 311. China Nootropics, by Form USD Million (2021-2026)
• Table 312. Japan Nootropics, by Application USD Million (2021-2026)
• Table 313. Japan Nootropics, by Drug USD Million (2021-2026)
• Table 314. Japan Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 315. Japan Nootropics, by Form USD Million (2021-2026)
• Table 316. India Nootropics, by Application USD Million (2021-2026)
• Table 317. India Nootropics, by Drug USD Million (2021-2026)
• Table 318. India Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 319. India Nootropics, by Form USD Million (2021-2026)
• Table 320. South Korea Nootropics, by Application USD Million (2021-2026)
• Table 321. South Korea Nootropics, by Drug USD Million (2021-2026)
• Table 322. South Korea Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 323. South Korea Nootropics, by Form USD Million (2021-2026)
• Table 324. Taiwan Nootropics, by Application USD Million (2021-2026)
• Table 325. Taiwan Nootropics, by Drug USD Million (2021-2026)
• Table 326. Taiwan Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 327. Taiwan Nootropics, by Form USD Million (2021-2026)
• Table 328. Australia Nootropics, by Application USD Million (2021-2026)
• Table 329. Australia Nootropics, by Drug USD Million (2021-2026)
• Table 330. Australia Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 331. Australia Nootropics, by Form USD Million (2021-2026)
• Table 332. Rest of Asia-Pacific Nootropics, by Application USD Million (2021-2026)
• Table 333. Rest of Asia-Pacific Nootropics, by Drug USD Million (2021-2026)
• Table 334. Rest of Asia-Pacific Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 335. Rest of Asia-Pacific Nootropics, by Form USD Million (2021-2026)
• Table 336. Europe Nootropics, by Country USD Million (2021-2026)
• Table 337. Europe Nootropics, by Application USD Million (2021-2026)
• Table 338. Europe Nootropics, by Drug USD Million (2021-2026)
• Table 339. Europe Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 340. Europe Nootropics, by Form USD Million (2021-2026)
• Table 341. Germany Nootropics, by Application USD Million (2021-2026)
• Table 342. Germany Nootropics, by Drug USD Million (2021-2026)
• Table 343. Germany Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 344. Germany Nootropics, by Form USD Million (2021-2026)
• Table 345. France Nootropics, by Application USD Million (2021-2026)
• Table 346. France Nootropics, by Drug USD Million (2021-2026)
• Table 347. France Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 348. France Nootropics, by Form USD Million (2021-2026)
• Table 349. Italy Nootropics, by Application USD Million (2021-2026)
• Table 350. Italy Nootropics, by Drug USD Million (2021-2026)
• Table 351. Italy Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 352. Italy Nootropics, by Form USD Million (2021-2026)
• Table 353. United Kingdom Nootropics, by Application USD Million (2021-2026)
• Table 354. United Kingdom Nootropics, by Drug USD Million (2021-2026)
• Table 355. United Kingdom Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 356. United Kingdom Nootropics, by Form USD Million (2021-2026)
• Table 357. Netherlands Nootropics, by Application USD Million (2021-2026)
• Table 358. Netherlands Nootropics, by Drug USD Million (2021-2026)
• Table 359. Netherlands Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 360. Netherlands Nootropics, by Form USD Million (2021-2026)
• Table 361. Rest of Europe Nootropics, by Application USD Million (2021-2026)
• Table 362. Rest of Europe Nootropics, by Drug USD Million (2021-2026)
• Table 363. Rest of Europe Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 364. Rest of Europe Nootropics, by Form USD Million (2021-2026)
• Table 365. MEA Nootropics, by Country USD Million (2021-2026)
• Table 366. MEA Nootropics, by Application USD Million (2021-2026)
• Table 367. MEA Nootropics, by Drug USD Million (2021-2026)
• Table 368. MEA Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 369. MEA Nootropics, by Form USD Million (2021-2026)
• Table 370. Middle East Nootropics, by Application USD Million (2021-2026)
• Table 371. Middle East Nootropics, by Drug USD Million (2021-2026)
• Table 372. Middle East Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 373. Middle East Nootropics, by Form USD Million (2021-2026)
• Table 374. Africa Nootropics, by Application USD Million (2021-2026)
• Table 375. Africa Nootropics, by Drug USD Million (2021-2026)
• Table 376. Africa Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 377. Africa Nootropics, by Form USD Million (2021-2026)
• Table 378. North America Nootropics, by Country USD Million (2021-2026)
• Table 379. North America Nootropics, by Application USD Million (2021-2026)
• Table 380. North America Nootropics, by Drug USD Million (2021-2026)
• Table 381. North America Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 382. North America Nootropics, by Form USD Million (2021-2026)
• Table 383. United States Nootropics, by Application USD Million (2021-2026)
• Table 384. United States Nootropics, by Drug USD Million (2021-2026)
• Table 385. United States Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 386. United States Nootropics, by Form USD Million (2021-2026)
• Table 387. Canada Nootropics, by Application USD Million (2021-2026)
• Table 388. Canada Nootropics, by Drug USD Million (2021-2026)
• Table 389. Canada Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 390. Canada Nootropics, by Form USD Million (2021-2026)
• Table 391. Mexico Nootropics, by Application USD Million (2021-2026)
• Table 392. Mexico Nootropics, by Drug USD Million (2021-2026)
• Table 393. Mexico Nootropics, by Distribution Channel USD Million (2021-2026)
• Table 394. Mexico Nootropics, by Form USD Million (2021-2026)
• Table 395. Nootropics Sales: by Application(K Tons)
• Table 396. Nootropics Sales ADHD , by Region K Tons (2021-2026)
• Table 397. Nootropics Sales Alzheimer , by Region K Tons (2021-2026)
• Table 398. Nootropics Sales Narcolepsy , by Region K Tons (2021-2026)
• Table 399. Nootropics Sales Memory Enhancement , by Region K Tons (2021-2026)
• Table 400. Nootropics Sales Mood and Depression , by Region K Tons (2021-2026)
• Table 401. Nootropics Sales Anxiety , by Region K Tons (2021-2026)
• Table 402. Nootropics Sales Others , by Region K Tons (2021-2026)
• Table 403. Nootropics Sales: by Drug(K Tons)
• Table 404. Nootropics Sales Prescription (Modafinil, Adderall, Methylphenidate, Memantine and Others) , by Region K Tons (2021-2026)
• Table 405. Nootropics Sales OTC (Omega-3s, Caffeine, L-Theanine, Racetams, Gingko Biloba, Creatine and Others) , by Region K Tons (2021-2026)
• Table 406. Nootropics Sales: by Distribution Channel(K Tons)
• Table 407. Nootropics Sales Online (E-Commerce Stores) , by Region K Tons (2021-2026)
• Table 408. Nootropics Sales Offline (Pharmacy, Super Markets, Hyper Markets, and Department Stores) , by Region K Tons (2021-2026)
• Table 409. Nootropics Sales: by Form(K Tons)
• Table 410. Nootropics Sales Powder , by Region K Tons (2021-2026)
• Table 411. Nootropics Sales Liquid , by Region K Tons (2021-2026)
• Table 412. Nootropics Sales Tablet , by Region K Tons (2021-2026)
• Table 413. Nootropics Sales Capsules , by Region K Tons (2021-2026)
• Table 414. South America Nootropics Sales, by Country K Tons (2021-2026)
• Table 415. South America Nootropics Sales, by Application K Tons (2021-2026)
• Table 416. South America Nootropics Sales, by Drug K Tons (2021-2026)
• Table 417. South America Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 418. South America Nootropics Sales, by Form K Tons (2021-2026)
• Table 419. Brazil Nootropics Sales, by Application K Tons (2021-2026)
• Table 420. Brazil Nootropics Sales, by Drug K Tons (2021-2026)
• Table 421. Brazil Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 422. Brazil Nootropics Sales, by Form K Tons (2021-2026)
• Table 423. Argentina Nootropics Sales, by Application K Tons (2021-2026)
• Table 424. Argentina Nootropics Sales, by Drug K Tons (2021-2026)
• Table 425. Argentina Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 426. Argentina Nootropics Sales, by Form K Tons (2021-2026)
• Table 427. Rest of South America Nootropics Sales, by Application K Tons (2021-2026)
• Table 428. Rest of South America Nootropics Sales, by Drug K Tons (2021-2026)
• Table 429. Rest of South America Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 430. Rest of South America Nootropics Sales, by Form K Tons (2021-2026)
• Table 431. Asia Pacific Nootropics Sales, by Country K Tons (2021-2026)
• Table 432. Asia Pacific Nootropics Sales, by Application K Tons (2021-2026)
• Table 433. Asia Pacific Nootropics Sales, by Drug K Tons (2021-2026)
• Table 434. Asia Pacific Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 435. Asia Pacific Nootropics Sales, by Form K Tons (2021-2026)
• Table 436. China Nootropics Sales, by Application K Tons (2021-2026)
• Table 437. China Nootropics Sales, by Drug K Tons (2021-2026)
• Table 438. China Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 439. China Nootropics Sales, by Form K Tons (2021-2026)
• Table 440. Japan Nootropics Sales, by Application K Tons (2021-2026)
• Table 441. Japan Nootropics Sales, by Drug K Tons (2021-2026)
• Table 442. Japan Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 443. Japan Nootropics Sales, by Form K Tons (2021-2026)
• Table 444. India Nootropics Sales, by Application K Tons (2021-2026)
• Table 445. India Nootropics Sales, by Drug K Tons (2021-2026)
• Table 446. India Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 447. India Nootropics Sales, by Form K Tons (2021-2026)
• Table 448. South Korea Nootropics Sales, by Application K Tons (2021-2026)
• Table 449. South Korea Nootropics Sales, by Drug K Tons (2021-2026)
• Table 450. South Korea Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 451. South Korea Nootropics Sales, by Form K Tons (2021-2026)
• Table 452. Taiwan Nootropics Sales, by Application K Tons (2021-2026)
• Table 453. Taiwan Nootropics Sales, by Drug K Tons (2021-2026)
• Table 454. Taiwan Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 455. Taiwan Nootropics Sales, by Form K Tons (2021-2026)
• Table 456. Australia Nootropics Sales, by Application K Tons (2021-2026)
• Table 457. Australia Nootropics Sales, by Drug K Tons (2021-2026)
• Table 458. Australia Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 459. Australia Nootropics Sales, by Form K Tons (2021-2026)
• Table 460. Rest of Asia-Pacific Nootropics Sales, by Application K Tons (2021-2026)
• Table 461. Rest of Asia-Pacific Nootropics Sales, by Drug K Tons (2021-2026)
• Table 462. Rest of Asia-Pacific Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 463. Rest of Asia-Pacific Nootropics Sales, by Form K Tons (2021-2026)
• Table 464. Europe Nootropics Sales, by Country K Tons (2021-2026)
• Table 465. Europe Nootropics Sales, by Application K Tons (2021-2026)
• Table 466. Europe Nootropics Sales, by Drug K Tons (2021-2026)
• Table 467. Europe Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 468. Europe Nootropics Sales, by Form K Tons (2021-2026)
• Table 469. Germany Nootropics Sales, by Application K Tons (2021-2026)
• Table 470. Germany Nootropics Sales, by Drug K Tons (2021-2026)
• Table 471. Germany Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 472. Germany Nootropics Sales, by Form K Tons (2021-2026)
• Table 473. France Nootropics Sales, by Application K Tons (2021-2026)
• Table 474. France Nootropics Sales, by Drug K Tons (2021-2026)
• Table 475. France Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 476. France Nootropics Sales, by Form K Tons (2021-2026)
• Table 477. Italy Nootropics Sales, by Application K Tons (2021-2026)
• Table 478. Italy Nootropics Sales, by Drug K Tons (2021-2026)
• Table 479. Italy Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 480. Italy Nootropics Sales, by Form K Tons (2021-2026)
• Table 481. United Kingdom Nootropics Sales, by Application K Tons (2021-2026)
• Table 482. United Kingdom Nootropics Sales, by Drug K Tons (2021-2026)
• Table 483. United Kingdom Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 484. United Kingdom Nootropics Sales, by Form K Tons (2021-2026)
• Table 485. Netherlands Nootropics Sales, by Application K Tons (2021-2026)
• Table 486. Netherlands Nootropics Sales, by Drug K Tons (2021-2026)
• Table 487. Netherlands Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 488. Netherlands Nootropics Sales, by Form K Tons (2021-2026)
• Table 489. Rest of Europe Nootropics Sales, by Application K Tons (2021-2026)
• Table 490. Rest of Europe Nootropics Sales, by Drug K Tons (2021-2026)
• Table 491. Rest of Europe Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 492. Rest of Europe Nootropics Sales, by Form K Tons (2021-2026)
• Table 493. MEA Nootropics Sales, by Country K Tons (2021-2026)
• Table 494. MEA Nootropics Sales, by Application K Tons (2021-2026)
• Table 495. MEA Nootropics Sales, by Drug K Tons (2021-2026)
• Table 496. MEA Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 497. MEA Nootropics Sales, by Form K Tons (2021-2026)
• Table 498. Middle East Nootropics Sales, by Application K Tons (2021-2026)
• Table 499. Middle East Nootropics Sales, by Drug K Tons (2021-2026)
• Table 500. Middle East Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 501. Middle East Nootropics Sales, by Form K Tons (2021-2026)
• Table 502. Africa Nootropics Sales, by Application K Tons (2021-2026)
• Table 503. Africa Nootropics Sales, by Drug K Tons (2021-2026)
• Table 504. Africa Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 505. Africa Nootropics Sales, by Form K Tons (2021-2026)
• Table 506. North America Nootropics Sales, by Country K Tons (2021-2026)
• Table 507. North America Nootropics Sales, by Application K Tons (2021-2026)
• Table 508. North America Nootropics Sales, by Drug K Tons (2021-2026)
• Table 509. North America Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 510. North America Nootropics Sales, by Form K Tons (2021-2026)
• Table 511. United States Nootropics Sales, by Application K Tons (2021-2026)
• Table 512. United States Nootropics Sales, by Drug K Tons (2021-2026)
• Table 513. United States Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 514. United States Nootropics Sales, by Form K Tons (2021-2026)
• Table 515. Canada Nootropics Sales, by Application K Tons (2021-2026)
• Table 516. Canada Nootropics Sales, by Drug K Tons (2021-2026)
• Table 517. Canada Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 518. Canada Nootropics Sales, by Form K Tons (2021-2026)
• Table 519. Mexico Nootropics Sales, by Application K Tons (2021-2026)
• Table 520. Mexico Nootropics Sales, by Drug K Tons (2021-2026)
• Table 521. Mexico Nootropics Sales, by Distribution Channel K Tons (2021-2026)
• Table 522. Mexico Nootropics Sales, by Form K Tons (2021-2026)
• Table 523. Research Programs/Design for This Report
• Table 524. Key Data Information from Secondary Sources
• Table 525. Key Data Information from Primary Sources

• Figure 1. Porters Five Forces
• Figure 2. Supply/Value Chain
• Figure 3. PESTEL analysis
• Figure 4. Global Nootropics: by Application USD Million (2015-2020)
• Figure 5. Global Nootropics: by Drug USD Million (2015-2020)
• Figure 6. Global Nootropics: by Distribution Channel USD Million (2015-2020)
• Figure 7. Global Nootropics: by Form USD Million (2015-2020)
• Figure 8. South America Nootropics Share (%), by Country
• Figure 9. Asia Pacific Nootropics Share (%), by Country
• Figure 10. Europe Nootropics Share (%), by Country
• Figure 11. MEA Nootropics Share (%), by Country
• Figure 12. North America Nootropics Share (%), by Country
• Figure 13. Global Nootropics: by Application K Tons (2015-2020)
• Figure 14. Global Nootropics: by Drug K Tons (2015-2020)
• Figure 15. Global Nootropics: by Distribution Channel K Tons (2015-2020)
• Figure 16. Global Nootropics: by Form K Tons (2015-2020)
• Figure 17. South America Nootropics Share (%), by Country
• Figure 18. Asia Pacific Nootropics Share (%), by Country
• Figure 19. Europe Nootropics Share (%), by Country
• Figure 20. MEA Nootropics Share (%), by Country
• Figure 21. North America Nootropics Share (%), by Country
• Figure 22. Global Nootropics share by Players 2020 (%)
• Figure 23. Global Nootropics share by Players (Top 3) 2020(%)
• Figure 24. Global Nootropics share by Players (Top 5) 2020(%)
• Figure 25. BCG Matrix for key Companies
• Figure 26. Purelife Bioscience Co., Ltd. (China) Revenue, Net Income and Gross profit
• Figure 27. Purelife Bioscience Co., Ltd. (China) Revenue: by Geography 2020
• Figure 28. Cephalon, Inc. (United States) Revenue, Net Income and Gross profit
• Figure 29. Cephalon, Inc. (United States) Revenue: by Geography 2020
• Figure 30. HVMN Inc. (United States) Revenue, Net Income and Gross profit
• Figure 31. HVMN Inc. (United States) Revenue: by Geography 2020
• Figure 32. Accelerated Intelligence, Inc. (United Kingdom) Revenue, Net Income and Gross profit
• Figure 33. Accelerated Intelligence, Inc. (United Kingdom) Revenue: by Geography 2020
• Figure 34. AlternaScript (United States) Revenue, Net Income and Gross profit
• Figure 35. AlternaScript (United States) Revenue: by Geography 2020
• Figure 36. TruBrain (United States) Revenue, Net Income and Gross profit
• Figure 37. TruBrain (United States) Revenue: by Geography 2020
• Figure 38. Peak Nootropics (United States) Revenue, Net Income and Gross profit
• Figure 39. Peak Nootropics (United States) Revenue: by Geography 2020
• Figure 40. Nootrico (United States) Revenue, Net Income and Gross profit
• Figure 41. Nootrico (United States) Revenue: by Geography 2020
• Figure 42. NooCube (Cyprus) Revenue, Net Income and Gross profit
• Figure 43. NooCube (Cyprus) Revenue: by Geography 2020
• Figure 44. Opti-Nutra Ltd. (United Kingdom) Revenue, Net Income and Gross profit
• Figure 45. Opti-Nutra Ltd. (United Kingdom) Revenue: by Geography 2020
• Figure 46. Global Nootropics: by Application USD Million (2021-2026)
• Figure 47. Global Nootropics: by Drug USD Million (2021-2026)
• Figure 48. Global Nootropics: by Distribution Channel USD Million (2021-2026)
• Figure 49. Global Nootropics: by Form USD Million (2021-2026)
• Figure 50. South America Nootropics Share (%), by Country
• Figure 51. Asia Pacific Nootropics Share (%), by Country
• Figure 52. Europe Nootropics Share (%), by Country
• Figure 53. MEA Nootropics Share (%), by Country
• Figure 54. North America Nootropics Share (%), by Country
• Figure 55. Global Nootropics: by Application K Tons (2021-2026)
• Figure 56. Global Nootropics: by Drug K Tons (2021-2026)
• Figure 57. Global Nootropics: by Distribution Channel K Tons (2021-2026)
• Figure 58. Global Nootropics: by Form K Tons (2021-2026)
• Figure 59. South America Nootropics Share (%), by Country
• Figure 60. Asia Pacific Nootropics Share (%), by Country
• Figure 61. Europe Nootropics Share (%), by Country
• Figure 62. MEA Nootropics Share (%), by Country
• Figure 63. North America Nootropics Share (%), by Country

• Purelife Bioscience Co., Ltd. (China)
• Cephalon, Inc. (United States)
• HVMN Inc. (United States)
• Accelerated Intelligence, Inc. (United Kingdom)
• AlternaScript (United States)
• TruBrain (United States)
• Peak Nootropics (United States)
• Nootrico (United States)
• NooCube (Cyprus)
• Opti-Nutra Ltd. (United Kingdom)